Möchten Sie immer auf dem neuesten Stand bleiben?

Preliminary results indicate HHT patients are significantly impacted by bleeding events, with consistency in severity reporting at months one and three of the study Final study analysis will inform...

WATERTOWN, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company focused on correcting dysregulated signaling with clustering antibodies that address the underlying...

Biotech veteran will lead clinical development of Diagonal’s clustering antibody pipeline, including DIAG723 for hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH) ...

Diagonal Therapeutics today announced that both the FDA and EMA have granted orphan drug designations to DIAG723 for the treatment of HHT.

Results demonstrate potential of Company’s clustering antibody approach to address key challenges in HHT disease manifestations: restoring ALK1-mediated cellular signaling, preventing and reversing...

Diagonal Therapeutics today announced the initiation of a natural history study for HHT in partnership with patient advocacy group Cure HHT.

Diagonal Therapeutics to Present Data at ASH 2024 Demonstrating the Economic and Clinical Burden of Hereditary Hemorrhagic Telangiectasia (HHT)

Diagonal Therapeutics to Present at the Cure HHT’s 15th International Scientific Conference

Diagonal Therapeutics Launches with $128 Million in Financing to Pioneer a New Approach to Discovering and Developing Agonist Antibodies